U.S. markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.76
    +0.05 (+0.11%)
     
  • Gold

    1,806.30
    +0.80 (+0.04%)
     
  • Silver

    23.39
    +0.02 (+0.10%)
     
  • EUR/USD

    1.1923
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • GBP/USD

    1.3386
    +0.0004 (+0.03%)
     
  • USD/JPY

    104.3700
    -0.0700 (-0.07%)
     
  • BTC-USD

    18,661.83
    +12.76 (+0.07%)
     
  • CMC Crypto 200

    368.46
    -2.05 (-0.55%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    0.00 (0.00%)
     

Recap: Strongbridge Biopharma Q1 Earnings

Benzinga Insights
·1 min read

Shares of Strongbridge Biopharma (NASDAQ:SBBP) were flat in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 24.00% year over year to ($0.19), which beat the estimate of ($0.22).

Revenue of $6,674,000 rose by 53.67% from the same period last year, which beat the estimate of $5,940,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Strongbridge Biopharma hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: May 06, 2020

View more earnings on SBBP

Webcast URL: https://edge.media-server.com/mmc/p/wowsnib7

Recent Stock Performance

52-week high: $3.67

52-week low: $1.43

Price action over last quarter: Up 4.56%

Company Profile

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.